  Acute lymphoblastic leukemia (ALL) is a heterogeneous hematologic malignancy
involving the abnormal proliferation of immature lymphocytes, accounting for
most pediatric cancer cases. ALL management in children has seen great
improvement in the last decades thanks to better understanding of the disease
leading to improved treatment strategies evidenced through clinical trials.
Commonly a first course of chemotherapy (induction phase) is administered,
followed by treatment with a combination of anti-leukemia drugs. A measure of
the efficacy early in the course of therapy is minimal residual disease (MRD).
MRD quantifies residual tumor cells and indicates the effectiveness of the
treatment over the course of therapy. MRD positivity is defined for values of
MRD greater than 0.01%, yielding left-censored observations. We propose a
Bayesian model to study the relationship between patient features and MRD
observed at two time points during the induction phase. Specifically, we model
the observed MRD values via an auto-regressive model, accounting for
left-censoring of the data and for the fact that some patients are already in
remission after the induction phase. Patient characteristics are included in
the model via linear regression terms. In particular, patient-specific drug
sensitivity based on ex-vivo assays of patient samples is exploited to identify
groups of subjects with similar profiles. We include this information as a
covariate in the model for MRD. We adopt horseshoe priors for the regression
coefficients to perform variable selection to identify important covariates. We
fit the proposed approach to data from three prospective pediatric ALL clinical
trials carried out at the St. Jude Children's Research Hospital. Our results
highlight that drug sensitivity profiles and leukemic subtypes play an
important role in the response to induction therapy as measured by serial MRD
measures.
